Intelligent Chemical Structure Browser for Drug Discovery and Optimization
用于药物发现和优化的智能化学结构浏览器
基本信息
- 批准号:10386918
- 负责人:
- 金额:$ 72.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-02-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AlgorithmsAnimalsBiological AssayChemical StructureChemicalsChemistryClinicalClinical TrialsComplexComputer softwareCost SavingsDataDatabasesDevelopmentDiseaseDrug CompoundingEffectivenessFDA approvedGraphHeadIngestionIntelligenceIntuitionInvestmentsLeadLibrariesMapsMarket ResearchMethodologyMethodsModelingMolecular StructureMutateNeighborhoodsPathway AnalysisPathway interactionsPerceptionPerformancePharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhaseProbabilityProcessPropertyPsyche structureResourcesSafetyScientistSeriesSiteStructureStructure-Activity RelationshipSuggestionTechnologyTestingTextbooksThinkingTimeTranslatingVisionautomated analysisbasechemical groupdrug candidatedrug discoveryexperiencegraspimprovedinnovationlead candidatelead seriesnovelnovel therapeuticsoperationparallelizationperformance testsscaffoldsuccess
项目摘要
PROJECT SUMMARY
Collaborative Drug Discovery, Inc. (CDD) proposes to develop a novel intelligent data browser that will enable
medicinal chemists developing new drug compounds to more efficiently browse and organize experimental
data in an intuitive way. The proposed browser will essentially “hyperlink” chemical space and allow chemists
to navigate easily among compounds in a chemical lead series following the same pathways that lead from one
compound to the next in the mental models that they intuitively map in their heads. Navigating through and
extending a lead series to discover the optimal drug candidate to advance into animal studies and clinical trials
comprises a critical stage of the drug discovery pipeline: the success of large subsequent investments depends
on making the right decision. This stage also especially emphasizes creative and intuitive thinking. Existing
software that assists scientists engaged in this task tabulates data in formats that make it difficult to assemble
and compare the essential data needed to rapidly explore ideas about how to further optimize promising
candidates. Our proposed intelligent browser will support more natural and intuitive workflows.
A key enabling innovation for this technology is a methodology that we have developed to organize
molecular structures through a partial ordering based on the substructure-superstructure relation as a Hasse
diagram. Our semilattice representation provides a machine computable format that can capture the
relationships among related chemical entities that a medicinal chemist intuits.
Expected key impacts include (1) faster development of lead series into drug candidates, (2) cost savings due
to more efficient use of synthesis and assay resources, and most importantly (3) better scientific decisions
about which compounds to pursue and advance into the clinical pipeline. Better decisions at this stage in the
drug discovery process should increase the probability that drug candidates that are chosen will successfully
emerge through the clinical pipeline as FDA approved drugs, and improve the effectiveness and safety profile of
those drugs. Even a small increase in these probabilities multiplied by the size of the investments required to
take drugs through clinical trials translates into a large value. We have validated this perception of value in
preliminary market research with potential pharmaceutical company customers.
!
项目概要
Collaborative Drug Discovery, Inc. (CDD) 提议开发一种新型智能数据浏览器,该浏览器将能够
药物化学家开发新药物化合物以更有效地浏览和组织实验
所提议的浏览器本质上将“超链接”化学空间,并允许化学家以直观的方式查看数据。
遵循与其中一种化学先导物相同的路径,轻松地在化学先导物系列中的化合物之间导航
复合到他们在头脑中直观地映射的心理模型中的下一个。
扩展先导系列以发现最佳候选药物,以推进动物研究和临床试验
包括药物发现管道的关键阶段:大规模后续投资的成功取决于
这个阶段还特别强调现有的创造性和直觉思维。
帮助科学家从事这项任务的软件以难以组装的格式列出数据
并比较快速探索如何进一步优化有前途的想法所需的基本数据
我们提出的智能浏览器将支持更自然和直观的工作流程。
这项技术的关键创新是我们开发的一种方法来组织
通过基于子结构-上层结构关系的偏序作为 Hasse 的分子结构
我们的半格子表示提供了一种机器可计算的格式,可以捕获
药物化学家凭直觉得出的相关化学实体之间的关系。
预期的关键影响包括(1)更快地将先导系列开发成候选药物,(2)由于
更有效地利用合成和分析资源,最重要的是 (3) 更好的科学决策
关于在现阶段寻求哪些化合物并将其推进临床管道的更好决策。
药物发现过程应该增加所选候选药物成功的可能性
作为 FDA 批准的药物进入临床管道,并提高药物的有效性和安全性
即使是小幅增加药物的概率乘以所需的投资规模。
通过临床试验将药物转化为巨大的价值,我们已经验证了这种价值观念。
与潜在制药公司客户进行初步市场研究。
!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BARRY A BUNIN其他文献
BARRY A BUNIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BARRY A BUNIN', 18)}}的其他基金
Automated Molecular Identity Disambiguator (AutoMID)
自动分子身份消歧器 (AutoMID)
- 批准号:
10357906 - 财政年份:2020
- 资助金额:
$ 72.73万 - 项目类别:
Automated Molecular Identity Disambiguator (AutoMID)
自动分子身份消歧器 (AutoMID)
- 批准号:
10569639 - 财政年份:2020
- 资助金额:
$ 72.73万 - 项目类别:
Intelligent Chemical Structure Browser for Drug Discovery and Optimization
用于药物发现和优化的智能化学结构浏览器
- 批准号:
10241834 - 财政年份:2019
- 资助金额:
$ 72.73万 - 项目类别:
A Robust, Secure Framework to Effortlessly Bind Distributed Databases and Analysis Tools into Tightly Integrated Translational Drug Discovery Computational Platforms
一个强大、安全的框架,可以轻松地将分布式数据库和分析工具绑定到紧密集成的转化药物发现计算平台中
- 批准号:
10484172 - 财政年份:2019
- 资助金额:
$ 72.73万 - 项目类别:
Digital representation of chemical mixtures to aid drug discovery and formulation
化学混合物的数字表示以帮助药物发现和配制
- 批准号:
9902210 - 财政年份:2019
- 资助金额:
$ 72.73万 - 项目类别:
A Robust, Secure Framework to Effortlessly Bind Distributed Databases and Analysis Tools into Tightly Integrated Translational Drug Discovery Computational Platforms
一个强大、安全的框架,可以轻松地将分布式数据库和分析工具绑定到紧密集成的转化药物发现计算平台中
- 批准号:
10685358 - 财政年份:2019
- 资助金额:
$ 72.73万 - 项目类别:
Novel deep learning strategy to better predict pharmacological properties of candidate drugs and focus discovery efforts
新颖的深度学习策略可以更好地预测候选药物的药理学特性并集中发现工作
- 批准号:
10133177 - 财政年份:2018
- 资助金额:
$ 72.73万 - 项目类别:
Novel deep learning strategy to better predict pharmacological properties of candidate drugs and focus discovery efforts
新颖的深度学习策略可以更好地预测候选药物的药理学特性并集中发现工作
- 批准号:
10004481 - 财政年份:2018
- 资助金额:
$ 72.73万 - 项目类别:
相似国自然基金
乳酸介导的组蛋白乳酸化调控哺乳动物主要合子基因组激活的机制研究
- 批准号:82301880
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
早期环境暴露对儿童哮喘免疫保护的动物实验和机制研究
- 批准号:82300031
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于供应链视角的动物源性食品中抗微生物药物耐药性传导机制及监管策略研究
- 批准号:72303209
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
热带森林土壤氮添加下微节肢动物对氮转化过程的调控
- 批准号:32360323
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
Slc39a13在哺乳动物铁代谢中的作用
- 批准号:32371226
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA Replicons
研究 RNA 复制子诱导的 SIV/HIV T 和 B 细胞免疫的保护功效
- 批准号:
10673223 - 财政年份:2023
- 资助金额:
$ 72.73万 - 项目类别:
Elucidating causal mechanisms of ethanol-induced analgesia in BXD recombinant inbred mouse lines
阐明 BXD 重组近交系小鼠乙醇诱导镇痛的因果机制
- 批准号:
10825737 - 财政年份:2023
- 资助金额:
$ 72.73万 - 项目类别:
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression
优化结核分枝杆菌多药治疗以实现快速灭菌和耐药性抑制
- 批准号:
10567327 - 财政年份:2023
- 资助金额:
$ 72.73万 - 项目类别:
miR-137 Regulation of Intrinsic Excitability
miR-137 内在兴奋性的调节
- 批准号:
10719579 - 财政年份:2023
- 资助金额:
$ 72.73万 - 项目类别:
Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease
使用多药理学方法的小分子联合疗法作为罕见骨病的新型治疗范例
- 批准号:
10759694 - 财政年份:2023
- 资助金额:
$ 72.73万 - 项目类别: